Human papillomavirus type 16 E7 oncogene (HPV16 E7)

The Human papillomavirus type 16 (HPV16) E7 oncogene is a critical genetic component of the high-risk HPV16 virus, responsible for the majority of HPV-associated malignancies (National Cancer Institute, 2023). Its primary biological role involves the production of the E7 oncoprotein, which binds to and promotes the degradation of the retinoblastoma protein (pRb), thereby bypassing cell cycle checkpoints and promoting uncontrolled cell division (UniProt, 2024). In the context of disease, the persistent expression of the E7 gene is essential for the initiation and maintenance of the malignant phenotype in cervical, oropharyngeal, and other anogenital cancers (PubMed, PMID: 29113324). As a therapeutic target, the DNA sequence is addressed through various modalities, including DNA vaccines like VGX-3100 that prime the immune system to recognize E7-expressing cells and gene-editing technologies like CRISPR/Cas9 designed to permanently disrupt the viral genome (ClinicalTrials.gov, NCT03721068; PubMed, PMID: 31534003). Targeting the E7 sequence is particularly attractive because it is a foreign viral gene not present in healthy human cells, potentially offering high specificity. Current clinical efforts focus on therapeutic vaccines and RNA interference to silence its expression and restore normal cell cycle control (PubMed, PMID: 33458174).

Other names

HPV-16 E7 geneHuman papillomavirus 16 E7HPV16 early protein 7 geneHPV16 E7 DNA sequence

Therapeutic strategies include DNA vaccination to elicit a T-cell response against cells harboring the viral DNA, and gene-editing technologies like CRISPR/Cas9 to directly cleave and disrupt the oncogenic sequence (PubMed, PMID: 31534003; ClinicalTrials.gov, NCT03721068).